イリノテカンの注射反応と重度の毒性の関連性
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
PubMedで要約を見る
まとめ
この要約は機械生成です。CES1 と ABCG2 の遺伝的変異は,中性不全を含む重度のイリノテカンの毒性のリスクを増加させる可能性があります. イリノテカンの投与における潜在的な臨床応用のために,これらの発見を確認するためにさらなる研究が必要である.
科学分野
- ファルマゲノミクス
- 腫瘍学
- 臨床毒理学
背景
- イリノテカンの治療は,胃腸,血液,および輸液関連の急性コレリン症候群 (ACS) を含む重大な毒性に関連しています.
- UGT1A1の遺伝的変異は既知の危険因子であるが,他の遺伝子のイリノテカンの毒性への影響は十分に研究されていない.
研究 の 目的
- カーボキシルエステラーゼ (CES) 遺伝子の遺伝子変異と,イリノテカン関連急性コレリン症候群 (ACS) の関連性を調査する.
- イリノテカンの他の薬理学遺伝子 (CES1,CES2,UGT1A7,UGT1A9,ABCB1,ABCG2,ABCC2,SLCO1B1) の変異が重篤な毒性,治療改変,下痢,中性子減少症に与える影響を調査する.
主な方法
- 既定のイリノテカン (180 mg/ m2) を投与した93人の患者の復元分析.
- 主要な分析は,CES遺伝子変異と注射に関連するACSに焦点を当てた.
- 二次分析では,UGT1A1の遺伝子型を調整して,他の遺伝子変異と様々な毒性エンドポイントを調査した.
主要な成果
- CES1の変異は,注射に関連するACSと有意に関連していなかった.
- CES1 rs3785161 AA遺伝子型は,重度のイリノテカンの毒性の発生率 (37%対16%,P=0. 034) と関連していた.
- ABCG2 rs2231142 AA/ AC遺伝子型は重度の中性不全のリスク増加と関連していた (33%対8%,P=0. 017).
結論
- CES1 と ABCG2 の特定の遺伝的変異は,重度のイリノテカンの毒性および中性不全のリスクを増加させる可能性があります.
- これらの発見は,遺伝学によるイリノテカンの投与戦略の可能性を示唆しています.
- これらの関連性を確認し,臨床的有用性を調べるために,さらなる検証試験が必要である.
関連する概念動画
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
When toxic substances penetrate the human body, they disseminate to various tissues, undergoing metabolic changes. This process yields reactive metabolites that may covalently bind with specific target molecules, resulting in toxicity.
Toxicity falls into two primary categories: local and systemic.
Local toxicity appears at the exposure site, such as protein denaturation caused by caustic substances.
In contrast, systemic toxicity requires the toxic agent's absorption and distribution,...
The biliary system of the liver, crucial for bile secretion and drug excretion, comprises intrahepatic bile ducts that merge to form the common hepatic duct. This duct, carrying hepatic bile, combines with the cystic duct, draining the gallbladder and forming the common bile duct, which empties into the duodenum. Bile, produced by hepatic cells lining the bile canaliculi, is composed primarily of water, bile salts, pigments, electrolytes, and lesser amounts of cholesterol and fatty acids. Bile...